Search
Daxdilimab
go.drugbank.com/drugs/DB16391InvestigationalDaxdilimab is under investigation in clinical trial NCT04526912 (Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection).
IMA901
go.drugbank.com/drugs/DB06628InvestigationalIMA901 is a vaccine consists of tumor-associated peptides (TUMAPs).
BMS-488043
go.drugbank.com/drugs/DB05532ExperimentalBMS-488043 has been investigated as an anti-HIV agent.
Tengonermin
go.drugbank.com/drugs/DB16689InvestigationalTengonermin, also known as NGR-hTNF, is a vascular-targeting drug. … [A233270] A study also demonstrated that binding of the NGR-motif to CD13 determined both the homing of NGR-hTNF to tumor vessels and the increase in its antiangiogenic activity.[A233270]
AT3022
go.drugbank.com/drugs/DB05172ExperimentalAT3022, the Altea Therapeutics’s fentanyl citrate transdermal patch designed to provide safe and rapid management of moderate to severe chronic pain.
Pomisartan
go.drugbank.com/drugs/DB20188ExperimentalPomisartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Pomisartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic). … Pomisartan has a monoisotopic molecular weight of 490.24 Da.
Milfasartan
go.drugbank.com/drugs/DB20355ExperimentalMilfasartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Milfasartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic). … Milfasartan has a monoisotopic molecular weight of 554.21 Da.
Nicotinamide riboside
go.drugbank.com/drugs/DB14933ApprovedInvestigationalWithdrawnNicotinamide riboside is under investigation in clinical trial NCT03432871 (Nicotinamide Riboside and Mitochondrial Biogenesis).
Aminobenzoic acid
go.drugbank.com/drugs/DB02362ApprovedWithdrawnA member of the vitamin B complex. It used to be common in sunscreening agents until found to also be a sensitizer. The potassium salt is used therapeutically in fibrotic skin disorders.
Danvatirsen
go.drugbank.com/drugs/DB14825InvestigationalDanvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).